Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors ...Middle East

--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86...

Hence then, the article about ascletis announces first patient dosed in the u s phase i clinical trial of oral pd l1 small molecule inhibitor prodrug asc61 for treatment of advanced solid tumors was published today ( Monday 08/08/2022 - 03:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors )

Also on site :

• Crash, shooting near Sacramento-area gym leaves 2 injured; Suspect sought
• Grey's Anatomy Brings Back Meredith And Nick For A Tense Reunion — And A Big Question About Their Future
• Trump says US still ‘watching Iran‘ as ‘massive’ fleet heads to Gulf region